The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cediranib (C) in patients (pts) with malignant mesothelioma (MM): A phase II trial of The University of Chicago Phase II Consortium.
N. P. Campbell
No relevant relationships to disclose
R. Kunnavakkam
No relevant relationships to disclose
N. B. Leighl
Research Funding - AstraZeneca; Roche
M. D. Vincent
No relevant relationships to disclose
D. R. Gandara
Consultant or Advisory Role - AstraZeneca
M. Koczywas
Honoraria - Genentech; Lilly
B. J. Gitlitz
No relevant relationships to disclose
E. S. Agamah
No relevant relationships to disclose
S. P. Thomas
No relevant relationships to disclose
W. M. Stadler
No relevant relationships to disclose
E. E. Vokes
No relevant relationships to disclose
H. L. Kindler
Consultant or Advisory Role - AstraZeneca